Page last updated: 2024-12-06

2',3'-dideoxyadenosine 5'-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2',3'-dideoxyadenosine 5'-phosphate, also known as ddA, is a synthetic nucleoside analog that acts as a chain terminator during DNA synthesis. It is structurally similar to deoxyadenosine, but lacks the 2' and 3' hydroxyl groups on the ribose sugar. This modification prevents the addition of further nucleotides to the growing DNA chain. ddA is an important component of some antiviral therapies, including the treatment of HIV infection. The absence of the 2' and 3' hydroxyl groups prevents the formation of the phosphodiester bond required for chain elongation. This makes ddA a potent inhibitor of DNA polymerase, which is the enzyme responsible for replicating DNA. The ability of ddA to block DNA synthesis has led to its use as a therapeutic agent against various viruses, including HIV. ddA is typically administered in combination with other antiviral agents. The study of ddA is essential for understanding the mechanisms of viral replication and for developing new antiviral therapies. Research into ddA has provided valuable insights into the structure and function of DNA polymerase, and has led to the development of other potent antiviral drugs.'

Cross-References

ID SourceID
PubMed CID65356
CHEMBL ID1162296
SCHEMBL ID285262
MeSH IDM0055382

Synonyms (21)

Synonym
ddamp
nsc615566
107132-15-0
[(2s,5r)-5-(6-aminopurin-9-yl)tetrahydrofuran-2-yl]methyl dihydrogen phosphate
2',3-dideoxyadenosine 5'-monophosphate
[(2s,5r)-5-(6-aminopurin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
CHEMBL1162296 ,
2',3'-dideoxyadenosine 5'-phosphate
26315-32-2
2',3'-dideoxyadenosine monophosphate
5'-adenylic acid, 2',3'-dideoxy-
SCHEMBL285262
bdbm50478976
2',3'-dideoxyadenosine 5'-monophosphate
2DA ,
2',3'-dideoxyadenosine-5'-monophosphate
[(2s,5r)-5-(6-amino-9h-purin-9-yl)tetrahydrofuran-2-yl]methyl dihydrogen phosphate
Q27452910
((2s,5r)-5-(6-amino-9h-purin-9-yl)tetrahydrofuran-2-yl)methyl dihydrogen phosphate
[5-(6-amino-9h-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
DTXSID60910237
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Kd0.10000.00062.40599.8000AID341978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Activity0.25000.00091.30738.0000AID341977; AID341992
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID341992Inhibition of HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant assessed as dCTP level required to form 80% of binary enzyme complex formation with drug-terminated primer in posttranslocation state by site-specific foot printing assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID341978Binding affinity to ternary complex of HIV1 reverse transcriptase with primer/template in presence of dCTP substrate2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID341977Inhibition of HIV1 reverse transcriptase assessed as dCTP level required to form 80% of binary enzyme complex formation with drug-terminated primer in posttranslocation state by site-specific foot printing assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID341976Inhibition of HIV1 reverse transcriptase assessed as dCTP level required to form 50% of binary enzyme complex formation with drug-terminated primer in posttranslocation state by site-specific foot printing assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID341991Inhibition of HIV1 reverse transcriptase M41L/D67N/L210W/T215Y mutant assessed as dCTP level required to form 50% of binary enzyme complex formation with drug-terminated primer in posttranslocation state by site-specific foot printing assay2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.
AID1865852Prodrug conversion in inactivated fetal calf serum with RPMI 1640 culture medium assessed as parent ddA formation at 0.00005 M measured at 50 to 150 hrs by HPLC analysis
AID1865859Prodrug conversion in human CEM-SS cell extract assessed as parent ddA formation at 0.00005 M measured at 50 to 150 hrs by HPLC analysis
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's6 (46.15)18.2507
2000's5 (38.46)29.6817
2010's0 (0.00)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]